{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-089531","form_type":"8-K","ticker":"VYNE","cik":"0001566044","company_name":"VYNE Therapeutics Inc.","filed_at":"2025-09-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.376186+00:00","generated_at":"2026-05-17T06:44:35.289822+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"VYNE receives Nasdaq bid price deficiency notice; 180-day cure period to March 2026","bullets":["Closing bid price of VYNE common stock below $1.00 for 30 consecutive business days.","180-day compliance period until March 10, 2026; stock continues trading on Nasdaq Capital Market.","Compliance regained if bid price closes at $1.00+ for 10 consecutive trading days before deadline.","Company evaluating options; may seek second 180-day period if not compliant by March 10, 2026.","Failure to regain compliance could result in delisting of common stock."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-089531","json":"https://secwatch.observer/filing/0001104659-25-089531.json","markdown":"https://secwatch.observer/filing/0001104659-25-089531.md","text":"https://secwatch.observer/filing/0001104659-25-089531.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1566044/000110465925089531/0001104659-25-089531-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1566044/000110465925089531/tm2525917d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:44:35.289822+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a898fe6bf61dfd5c5ca58f124ffd3a405094dfc7","claim":"VYNE Therapeutics Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"September 11, 2025, VYNE Therapeutics Inc. (the “Company”) received notification from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the Company’s common stock (the “Common Stock”) was below $1.00 per share for 30 consecutive business days. The notification does not impact the listing of the Company’s Common Stock on the Nasdaq Capital Market at this time. In accordance with Nasdaq Listing Rule 5810(c)(3)","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1566044/000110465925089531/0001104659-25-089531-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2), 5810(c)(3)(A)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}